- Home
- LAUR vs ARWR Comparison
LAUR vs ARWR Comparison
Compare LAUR & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAUR
- ARWR
- Stock Information
- Founded
- LAUR 1989
- ARWR 2003
- Country
- LAUR United States
- ARWR United States
- Employees
- LAUR N/A
- ARWR N/A
- Industry
- LAUR Other Consumer Services
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- LAUR Real Estate
- ARWR Health Care
- Exchange
- LAUR Nasdaq
- ARWR Nasdaq
- Market Cap
- LAUR 4.3B
- ARWR 5.1B
- IPO Year
- LAUR 2017
- ARWR 1993
- Fundamental
- Price
- LAUR $28.88
- ARWR $40.29
- Analyst Decision
- LAUR Buy
- ARWR Strong Buy
- Analyst Count
- LAUR 3
- ARWR 8
- Target Price
- LAUR $30.33
- ARWR $47.75
- AVG Volume (30 Days)
- LAUR 981.3K
- ARWR 1.8M
- Earning Date
- LAUR 10-30-2025
- ARWR 11-25-2025
- Dividend Yield
- LAUR N/A
- ARWR N/A
- EPS Growth
- LAUR 35.40
- ARWR N/A
- EPS
- LAUR 1.68
- ARWR N/A
- Revenue
- LAUR $1,552,343,000.00
- ARWR $572,976,000.00
- Revenue This Year
- LAUR $6.53
- ARWR $21,287.22
- Revenue Next Year
- LAUR $8.15
- ARWR N/A
- P/E Ratio
- LAUR $17.19
- ARWR N/A
- Revenue Growth
- LAUR 0.44
- ARWR 2816.20
- 52 Week Low
- LAUR $15.18
- ARWR $9.57
- 52 Week High
- LAUR $31.74
- ARWR $40.75
- Technical
- Relative Strength Index (RSI)
- LAUR 43.27
- ARWR 69.43
- Support Level
- LAUR $28.84
- ARWR $36.73
- Resistance Level
- LAUR $30.48
- ARWR $39.56
- Average True Range (ATR)
- LAUR 0.68
- ARWR 1.80
- MACD
- LAUR -0.11
- ARWR -0.13
- Stochastic Oscillator
- LAUR 15.85
- ARWR 92.66
About LAUR Laureate Education Inc.
Laureate Education Inc is an international community of universities. The company provides higher education programs and services to students through an international network of licensed universities and higher education institutions. Its geographical segments include Peru and Mexico.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.